Aptamers Market to Hit $11.5B by 2030, Driven by Advancements

The global aptamers market is expected to develop at a 21.6% CAGR between 2022 and 2030. Sales in the sector are expected to reach $11.5 billion by 2030. The high prevalence of chronic diseases, as well as the increasing use of aptamers in R&D activities around the world, are expected to fuel growth during the assessment period (2022-2030).

Several countries throughout the world are increasing financing and making commitments for the development of innovative vaccines to tackle a wide range of diseases, including cancer. Numerous diseases have been successfully handled with the use of vaccinations and cutting-edge medicines. Aptamers market players are also expected to gain from the increased focus on chronic disease treatment and positive initiatives.

Aptamers are in high demand due to the growing healthcare needs of the aged population. According to the United States Census Bureau, more than 54 million individuals are above the age of 65. Growing elderly population is directly connected with an increase in chronic diseases, necessitating specialist treatment. Aptamers are widely employed in the development of innovative medicines, therefore demand is expected to increase during the projected period.

For Critical Insights on this Market, Request for More Info at: https://www.factmr.com/connectus/sample?flag=S&rep_id=173

Furthermore, North America is regarded the largest market for aptamers and is expected to stay such throughout the projection period. In North America, the United States is predicted to have a larger market share than Canada. In addition to North America, aptamer sales are expected to remain strong in Europe and Asia Pacific.

Furthermore, recent advances in drug administration, purification, and the development of medications for killing target cells are expected to push many researchers to choose aptamers due to their multiple competitive advantages. Some of the advantages over antibodies, such as low manufacturing costs, tiny molecular size, fewer side effects, and low immunogenicity, are expected to bode well for the worldwide aptamers market during the next ten years.

Why is the Adoption of Aptamers Low?

There is a lack of universal regulatory guidelines governing the quality and safety of aptamers, unlike other drugs and diagnostic tools. This issue is expected to hinder the demand for aptamers in developed regions like North America and Europe. The stringent approval regulations in these regions are also likely to limit the overall market potential throughout the forecast period.

Additionally, the lack of awareness about aptamers in developing and underdeveloped regions such as Asia Pacific, the Middle East, and Africa is expected to slow down aptamer sales over the next eight years.

What Can New Market Entrants Do to Make a Mark in This Industry?

Aptamers are still relatively new to the human market, and there remains significant unexplored potential in the aptamers industry due to the emerging nature of this technology. New players in the market have numerous opportunities to establish themselves and are expected to focus on expanding their research to accelerate product innovation.

In 2021, Xsensio, a Swiss digital health startup, collaborated with scientists at the Swiss Federal Institute of Technology Lausanne (EPFL) to develop a new graphene-based sensing system to detect the stress hormone cortisol in human sweat. The system uses a patch containing a graphene-based electrode and transistor. The graphene is functionalized with negatively charged aptamers, capturing cortisol upon contact to measure its concentration in sweat.

In December 2020, Basking Biosciences Inc., a privately-held biopharmaceutical company, announced the initial closing of a US$ 5.4 million seed series financing. The funds were allocated to the development of a next-generation treatment for acute ischemic stroke (AIS), utilizing DTRI-031, an RNA aptamer that inhibits von Willebrand Factor (vWF).

Key Segments in Aptamers Industry Research

• By Type :

  • Nucleic Acid Aptamers
    • DNA Aptamers
    • RNA Aptamers
    • XNA Aptamers
  • Peptide Aptamers

• By Application :

  • Diagnostics
  • Therapeutics
  • Research & Development
  • Others

• By Technology :

  • SELEX
  • X-aptamers
  • MARAS Technique
  • Others

• By End User :

  • Pharmaceutical & Biotechnology Companies
  • Academic & Government Research Institutes
  • CROs
  • Others

• By Region :

  • North America
  • Latin America
  • Europe
  • APAC
  • MEA

Contact:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Sales Team: sales@factmr.com
Follow Us: LinkedIn | Twitter | Blog